

# Muhlis Cem Ar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2553927/publications.pdf>

Version: 2024-02-01

106  
papers

807  
citations

516215

16  
h-index

676716

22  
g-index

106  
all docs

106  
docs citations

106  
times ranked

1211  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 presenting with immune thrombocytopenia: A case report and review of the literature. <i>Journal of Medical Virology</i> , 2021, 93, 43-45.	2.5	41
2	Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. <i>Leukemia Research</i> , 2014, 38, 781-787.	0.4	33
3	TheSOCS-1 gene methylation in chronic myeloid leukemia patients. <i>American Journal of Hematology</i> , 2007, 82, 729-730.	2.0	32
4	Methods for individualising factor VIII dosing in prophylaxis. <i>European Journal of Haematology</i> , 2014, 93, 16-20.	1.1	31
5	A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria. <i>BMC Hematology</i> , 2004, 4, 3.	2.6	28
6	Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. <i>Annals of Hematology</i> , 2005, 84, 609-613.	0.8	24
7	Extended Half-Life (EHL) Coagulation Factors: A New Era in the Management of Haemophilia Patients. <i>Turkish Journal of Haematology</i> , 2019, 36, 141-154.	0.2	23
8	Azacitidine has limited activity in "real life" patients with MDS and AML: a single centre experience. <i>Hematological Oncology</i> , 2012, 30, 76-81.	0.8	21
9	Unilateral sudden hearing loss as the first sign of chronic myeloid leukemia. <i>European Archives of Oto-Rhino-Laryngology</i> , 2007, 264, 1513-1516.	0.8	20
10	Intracranial extramedullary hematopoiesis in patients with thalassemia: a case report and review of the literature. <i>Transfusion</i> , 2012, 52, 1715-1720.	0.8	20
11	Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 804-811.	0.2	20
12	Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. <i>Hematology</i> , 2018, 23, 212-220.	0.7	20
13	How to treat myelodysplastic syndrome with clinical features resembling Behçet syndrome: a case-based systematic review. <i>Annals of Hematology</i> , 2020, 99, 1193-1203.	0.8	20
14	Severe Bone Marrow Failure Due to Valganciclovir Overdose After Renal Transplantation From Cadaveric Donors: Four Consecutive Cases. <i>Transplantation Proceedings</i> , 2009, 41, 1648-1653.	0.3	19
15	An eleven-year cohort of bloodstream infections in 552 febrile neutropenic patients: resistance profiles of Gram-negative bacteria as a predictor of mortality. <i>Annals of Hematology</i> , 2020, 99, 1925-1932.	0.8	19
16	Generics in chronic myeloid leukemia: current arguments for and against and the established evidence. <i>Expert Review of Hematology</i> , 2014, 7, 697-699.	1.0	18
17	Effects of Imatinib Mesylate on Renin-Angiotensin System (RAS) Activity during the Clinical Course of Chronic Myeloid Leukaemia. <i>Journal of International Medical Research</i> , 2009, 37, 1018-1028.	0.4	17
18	First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate. <i>British Journal of Haematology</i> , 2014, 167, 139-141.	1.2	17

#	ARTICLE	IF	CITATIONS
19	Personalized prophylaxis in people with hemophilia A: challenges and achievements. Expert Review of Hematology, 2016, 9, 1203-1208.	1.0	17
20	Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV (b) (b) EBV (b) (b) HHV8(+) patient. European Journal of Haematology, 2013, 91, 467-469.	1.1	15
21	Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis. Molecular Biology Reports, 2014, 41, 6737-6742.	1.0	15
22	Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. Turkish Journal of Haematology, 2013, 30, 351-358.	0.2	14
23	The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 2935-2937.	0.6	14
24	The Changing Epidemiology of Bloodstream Infections and Resistance in Hematopoietic Stem Cell Transplantation Recipients. Turkish Journal of Haematology, 2016, 33, 216-222.	0.2	14
25	Osteoporosis in Patients With Hemophilia: Single-Center Results From a Middle-Income Country. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961986168.	0.7	13
26	Essential Thrombocythemia and Multiple Myeloma: Two Rare Diseases in One Patient. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 442-445.	0.2	12
27	Portal Hypertension and Myeloproliferative Neoplasms: A Relationship Revealed. ISRN Hematology, 2013, 2013, 1-5.	1.6	12
28	Polycythemia vera: diagnosis, clinical course, and current management. Turkish Journal of Medical Sciences, 2018, 48, 698-710.	0.4	12
29	Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors. Leukemia and Lymphoma, 2019, 60, 200-207.	0.6	11
30	The Impact of Obesity and Insulin Resistance on Iron and Red Blood Cell Parameters: A Single Center, Cross-Sectional Study. Turkish Journal of Haematology, 2014, 31, 61-67.	0.2	10
31	Alemtuzumab in Sjögren syndrome: efficient but not innocent. European Journal of Dermatology, 2007, 17, 525-9.	0.3	10
32	A Polymorphism in the IL-5 Gene is Associated with Inhibitor Development in Severe Hemophilia A Patients. Turkish Journal of Haematology, 2014, 31, 17-24.	0.2	9
33	Patients treated with therapeutic plasma exchange: A single center experience. Transfusion and Apheresis Science, 2014, 51, 83-89.	0.5	9
34	Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode. Turkish Journal of Haematology, 2015, 32, 243-250.	0.2	9
35	The road to biosimilars in rare diseases – ongoing lessons from Gaucher disease. American Journal of Hematology, 2020, 95, 233-237.	2.0	9
36	Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score. Journal of Infection and Chemotherapy, 2021, 27, 1329-1335.	0.8	9

#	ARTICLE	IF	CITATIONS
37	The Impact of Prothrombotic Mutations on Factor Consumption in Adult Patients with Severe Hemophilia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 660-665.	0.7	8
38	Sarcoidosis mimicking lymphoma on positron emission tomography-computed tomography in two patients treated for lymphoma: two case reports. <i>Journal of Medical Case Reports</i> , 2009, 3, 7306.	0.4	8
39	Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study. <i>ISRN Hematology</i> , 2013, 2013, 1-9.	1.6	8
40	Critical appraisal of European LeukemiaNet (ELN) 2013 recommendations for the management of chronic myeloid leukemia: is it early for a warning?. <i>Expert Review of Hematology</i> , 2016, 9, 919-921.	1.0	8
41	Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study. <i>International Journal of Hematology</i> , 2017, 105, 70-78.	0.7	8
42	Acute hepatitis B despite a previous high titer of anti-HBs. <i>Hepatology International</i> , 2010, 4, 530-532.	1.9	7
43	Treatment of patients with immune thrombocytopenia admitted to the emergency room. <i>International Journal of Hematology</i> , 2016, 104, 216-222.	0.7	7
44	Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience. <i>Turkish Journal of Haematology</i> , 2017, 34, 291-299.	0.2	7
45	Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy. <i>Turkish Journal of Gastroenterology</i> , 2015, 25, 233-233.	0.4	7
46	Pulmonary radiological findings in patients with acute myeloid leukemia and their relation to chemotherapy and prognosis: a single center retrospective study. <i>Turkish Journal of Haematology</i> , 2011, 29, 217-22.	0.2	6
47	Comparison of International Prognostic Index and NCCN-IPI in 324 patients with <i>de novo</i> diffuse large B-cell lymphoma: a multi-center retrospective analysis. <i>Leukemia and Lymphoma</i> , 2016, 57, 1211-1214.	0.6	6
48	JAK2V617F Mutation Is Not Associated with Thrombosis in Behcet Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 421-426.	0.7	5
49	Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia. <i>Journal of Clinical Pathology</i> , 2016, 69, 810-816.	1.0	5
50	Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country. <i>Annals of Hematology</i> , 2020, 99, 2671-2677.	0.8	5
51	Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies. <i>Turkish Journal of Haematology</i> , 2022, 39, 43-54.	0.2	5
52	Variant Philadelphia translocations with different breakpoints in six chronic myeloid leukemia patients. <i>Turkish Journal of Haematology</i> , 2011, 28, 186-192.	0.2	4
53	Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single Institution Experience. <i>Balkan Medical Journal</i> , 2018, 35, 417-421.	0.3	4
54	Cost of hemophilia A in Turkey: an economic disease burden analysis. <i>Journal of Medical Economics</i> , 2021, 24, 1052-1059.	1.0	4

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 549-557.	0.2	4
56	Cytogenetic Clonal Evolution in Patients with Chronic Myeloid Leukemia. <i>Biotechnology and Biotechnological Equipment</i> , 2009, 23, 1515-1520.	0.5	3
57	Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. <i>Turkish Journal of Haematology</i> , 2014, 31, 374-380.	0.2	3
58	Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide. <i>Expert Review of Hematology</i> , 2015, 8, 765-783.	1.0	3
59	The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?. <i>Leukemia and Lymphoma</i> , 2015, 56, 1182-1183.	0.6	3
60	Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed-Refractory to IMiDs and Proteasome Inhibitors. <i>Turkish Journal of Haematology</i> , 2017, 34, 233-238.	0.2	3
61	Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e241.	0.2	3
62	The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e377-e384.	0.2	3
63	Copy-number variations in adult patients with chronic immune thrombocytopenia. <i>Expert Review of Hematology</i> , 2020, 13, 1277-1287.	1.0	3
64	Multidrug Resistance Gene (MDR1) C3435T Polymorphism and Imatinib Response in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2011, 118, 1692-1692.	0.6	3
65	Real-Life Data and a Single Center Experience on Dasatinib-Induced Pulmonary Arterial Hypertension in Patients with Philadelphia Chromosome-Positive Leukemias. <i>Blood</i> , 2015, 126, 4037-4037.	0.6	3
66	Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkinâ€™s or Non-Hodgkinâ€™s Lymphoma?. <i>Turkish Journal of Haematology</i> , 2015, 32, 213-9.	0.2	3
67	Determining T and B Cell development by TREC/KREC analysis in primary immunodeficiency patients and healthy controls. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13130.	1.3	3
68	Intracranial mass in a patient with thalassaemia major. <i>British Journal of Haematology</i> , 2011, 152, 126-126.	1.2	2
69	A Rare Entity in Multiple Myeloma: Six Nerve Paralysis. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2014, 30, 70-72.	0.3	2
70	Congenital Dyserythropoietic Anemia Type 1: Report of One Patient and Analysis of Previously Reported Patients Treated with Interferon Alpha. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 272-277.	0.3	2
71	Bronchus Associated Lymphoid Tissue Lymphoma Presenting with Immunodeficiency and Multiple Pulmonary Nodules. <i>Case Reports in Pulmonology</i> , 2017, 2017, 1-3.	0.2	2
72	Participation in Physical and Sportive Activities among Adult Turkish People with Hemophilia: A Single-Center Experience. <i>Turkish Journal of Haematology</i> , 2018, 35, 81-82.	0.2	2

#	ARTICLE	IF	CITATIONS
73	Results of multicenter registry for patients with inherited factor VII deficiency in Turkey. Scandinavian Journal of Clinical and Laboratory Investigation, 2022, 82, 28-36.	0.6	2
74	Next-Generation Sequencing Of The BCR-ABL1 Kinase Domain May Be Beneficial In Decision Making Among Chronic Myeloid Leukemia Patients With Tyrosine Kinase Inhibitor Resistance. Blood, 2013, 122, 384-384.	0.6	1
75	Imatinib Mesylate Reduces Bone Marrow Fibrosis and Overwhelms the Adverse Prognostic Impact of Reticulin Formation in Patients with Chronic Myeloid Leukemia. Blood, 2015, 126, 2783-2783.	0.6	1
76	The Real-Life Data on the Outcome of Hepatitis B Infection in Patients with B-Cell Lymphoproliferative Neoplasms Treated with Ibrutinib. Blood, 2019, 134, 4316-4316.	0.6	1
77	Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythaemia Vera: a Multicentre Chart Review Study. Turkish Journal of Haematology, 2020, 37, 177-185.	0.2	1
78	Minimal Residual Disease (MRD) Detection with Translocations and T-Cell Receptor and Immunoglobulin Gene Rearrangements in Adult Acute Lymphoblastic Leukaemia Patients: A Pilot Study. Turkish Journal of Haematology, 2008, 25, 124-32.	0.2	1
79	Renal recovery after acute kidney injury requiring urgent hemodialysis is not associated with improved survival of the patients with multiple myeloma. Irish Journal of Medical Science, 2022, , 1.	0.8	1
80	The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Turkish Journal of Haematology, 2012, 29, 242-247.	0.2	0
81	Recurrent Monosomies Confirmed by Interphase FISH in Three Chronic Myeloid Leukemia Cases. Turkish Journal of Haematology, 2015, 32, 82-84.	0.2	0
82	Current status of medical science in Turkey. Wiener Klinische Wochenschrift, 2016, 128, 557-558.	1.0	0
83	Comment and response to: the significance of early warning in chronic myeloid leukemia. Expert Review of Hematology, 2018, 11, 267-268.	1.0	0
84	Case report of a young patient with transthyretin amyloidosis associated with Gly67Ala mutation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 75-76.	1.4	0
85	Coexistence of Hermansky-Pudlak syndrome and JAK2V617F-positive essential thrombocythemia. Ultrastructural Pathology, 2019, 43, 94-98.	0.4	0
86	The impact of transfusion burden and comorbidities on the prognosis of patients with myelodysplastic syndromes. Transfusion and Apheresis Science, 2020, 59, 102845.	0.5	0
87	The prognostic value of serum levels of a proliferation-inducing ligand (APRIL) in treatment-naïve patients with chronic lymphocytic leukemia. Turkish Journal of Medical Sciences, 2021, 51, 348-354.	0.4	0
88	Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis. Hematology, Transfusion and Cell Therapy, 2021, , .	0.1	0
89	Ten-Year Follow-up Data of Diffuse Large B-Cell Lymphoma Patients: Single Center Experience. Blood, 2011, 118, 5223-5223.	0.6	0
90	CLLU1 Gene Expression Level As a Prognostic Parameter in Patients with Chronic Lymphocytic Leukemia. Blood, 2011, 118, 4603-4603.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Imatinib for Chronic Myeloid Leukemia Patients: A Single Institution Experience. <i>Blood</i> , 2011, 118, 4429-4429.	0.6	0
92	A Rare Skin Lesion Seen in Acute Myeloid Leukemia: Skin Infiltration. <i>İstanbul Medical Journal</i> , 2013, 14, 124-125.	0.1	0
93	The Prognostic Value of Serum APRIL Levels in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 5648-5648.	0.6	0
94	Posttransplant Secondary Neoplasms: A Single Center Experience. <i>Blood</i> , 2015, 126, 5485-5485.	0.6	0
95	Haemophilic Arthropathy Is a Risk Factor for Reduced Bone Mineral Density and Vitamin D Deficiency. <i>Blood</i> , 2015, 126, 4685-4685.	0.6	0
96	New CNV Regions Identified in ITP Provide Evidence for Genetic Predisposition. <i>Blood</i> , 2015, 126, 77-77.	0.6	0
97	A Splenic Marginal Zone Lymphoma Case Presenting with Cyanosis, Spider Angiomas, and Polycythemia. <i>İstanbul Medical Journal</i> , 2016, 16, 158-161.	0.1	0
98	Real-Life Data and a Single Center Experience on the Efficacy and Toxicity Profile of Imatinib in the Treatment of Elderly Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1905-1905.	0.6	0
99	Retrospective evaluation of hairy cell leukemia patients treated with 3 different first-line treatment modalities in the last two decades: a single center experience. <i>Turkish Journal of Haematology</i> , 0, , .	0.2	0
100	Cytogenetic Aberrations in Patients with Aplastic Anemia. <i>Turkiye Klinikleri Journal of Medical Sciences</i> , 2019, 39, 409-413.	0.1	0
101	Management of Major Surgical Procedures in Patients with Hemophilia: A Single-Center Experience of 49 Procedures. <i>Blood</i> , 2019, 134, 4933-4933.	0.6	0
102	Age-Related Co-Expression of BCOR and BCORL1 mRNA in Acute Myeloid Leukemia. <i>Clinical Laboratory</i> , 2020, 66, .	0.2	0
103	The Impact of the COVID-19 Pandemic on the Diagnosis and Management of Patients with Classical Hodgkin Lymphoma: A Single-Center Experience. <i>Blood</i> , 2021, 138, 1394-1394.	0.6	0
104	Treatment Responses, Toxicity and Survival in Patients with Classical Hodgkin Lymphoma Aged 50 Years and Older: A Single-Center Experience over 2 Decades. <i>Blood</i> , 2021, 138, 4541-4541.	0.6	0
105	The Impact of EUTOS Long-Term Survival (ELTS) Score on Predicting Progression and Survival Among Turkish Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4600-4600.	0.6	0
106	Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT. <i>Blood</i> , 2020, 136, 45-47.	0.6	0